Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade

Journal of Gene Medicine

Volumn 2, Issue 1, 2000, Pages 41-51

  Stein, Colleen S ^a   Martins, Inês ^a   Davidson, Beverly L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

CD154; Gene therapy; Hypercholesterolemia; Immunosuppression; Low density lipoprotein receptor; Recombinant adenovirus

Indexed keywords

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS;

CD40 LIGAND; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT DNA;

ADENOVIRUS; ANIMAL; ARTICLE; C57BL MOUSE; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; MOUSE; POLYMERASE CHAIN REACTION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; CHOLESTEROL; DNA, RECOMBINANT; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; INJECTIONS, INTRAPERITONEAL; LIVER; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RECEPTORS, LDL; RNA, MESSENGER;

EID: 0033644454     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(200001/02)2:1<41::aid-jgm79>3.0.co;2-p     Document Type: Article

References (50)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
2. Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
3. Ishibashi S, Goldstein JL, Brown MS, et al. Massive xanthomatosis and atherosclerosis in cholesterol-fed low denisity lipoprotein receptor-negative mice. J Clin Invest 1994; 93: 1885-1893.
4. Kozarsky KF, Jooss K, Donahee M, et al. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13: 54-62.
5. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-4411.
6. Tripathy SK, Black HB, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2(5): 545-550.
7. Song W, Kong H-L, Traktman P, et al. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum Gene Ther 1997; 8: 1207-1217.
8. Morral N, O'Neal W, Zhou H, et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997; 8: 1275-1286.
9. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1405.
10. Yang Y, Li Q, Ertl HC, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69(4): 2004-2015.
11. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
12. Kay MA, Holterman A-X, Meuse L, et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
13. Yang Y, Su Q, Grewal IS, et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70(9): 6370-6377.
14. Guérette B, Vilquin JT, Gingras M, et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 1996; 7: 1455-1463.
15. Kay MA, Meuse L, Gown AM, et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A 1997; 94: 4686-4691.
16. Scaria A, St. George JA, Gregory RJ, et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 1997; 4(6): 611-617.
17. Wilson CB, Embree LJ, Schowalter D, et al. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J Virol 1998; 72(9): 7542-7550.
18. Stein CS, Pemberton JL, van Rooijen N, et al. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Ther 1998; 5: 431-439.
19. Mondino A, Jenkins MK. Surface proteins involved in T-cell costimulation. J Leukoc Biol 1994; 55: 805-815.
20. Ranheim EA, Kipps TJ. Activated T-cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177(4): 925-935.
21. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dentritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-1272.
22. Roy M, Aruffo A, Ledbetter J, et al. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 1995; 25: 596-603.
23. Ding L, Green JM, Thompson CB, et al. B7/CD28-dependent and -independent induction of CD40 ligand expression. J Immunol 1995; 155: 5124-5132.
24. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996; 16: 59-108.
25. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38.
26. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A 1993; 90: 2812-2816.
27. Davidson BL, Doran SE, Shewach DS, et al. Expression of Escherichia coli β-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exp Neurol 1994; 125: 258-267.
28. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
29. de Silva HV, Más-Oliva J, Taylor JM, et al. Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse. J Lipid Res 1994; 35: 1297-1310.
30. Russell DW, Brown MS, Goldstein JL. Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. J Biol Chem 1989; 264: 21682-21688.
31. Brown DR, Brousseau ME, Shamburek RD, et al. Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins. Metabolism 1996; 45(12): 1447-1457.
32. Kozarsky KF, McKinley DR, Austin LL, et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702.
33. Seidel D. H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artif Organs 1996; 20(4): 303-310.
34. Bilheimer DW, Goldstein JL, Grundy SM, et al. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. New Engl J Med 1984; 311: 1658-1664.
35. Starzl TE, Bilheimer DW, Bahnson HT, et al. Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet 1984; June 23: 1382-1383.
36. Yao SN, Farjo A, Roessler BJ, et al. Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver. Viral Immunol 1996; 9(3): 141-153.
37. Wadsworth SC, Zhou H, Smith AE, et al. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J Virol 1997; 71(7): 5189-5196.
38. Boshart M, Weber F, Jahn G, et al. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 1985; 41: 521-530.
39. Ghazal P, Lubon H, Fleckenstein B, et al. Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci U S A 1987; 84: 3658-3662.
40. Sambucetti LC, Cherrington JM, Wilkinson GWG, et al. NF-κB activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T-cell stimulation. EMBO J 1989; 8(13): 4251-4258.
41. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutve NF-κB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995; 96: 2521-2527.
42. Prösch S, Staak K, Stein J, et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFα is mediated via induction of NF-κB. Virology 1995; 208: 197-206.
43. Löser P, Jennings GS, Strauss M, et al. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFκB. J Virol 1998; 72(1): 180-190.
44. Lieber A, He C-H, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71(11): 8798-8807.
45. Armentano D, Zabner J, Sacks C, et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71(3): 2408-2416.
46. Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
47. Harms JS, Splitter GA. Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995; 6: 1291-1297.
48. Worgall S, Wolff G, Falck-Pedersen E, et al. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
49. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
50. Morsy MA, Gu MC, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998; 95: 7866-7871.